Compounds > lonafarnib
Page last updated: 2024-09-04

lonafarnib and abemaciclib

lonafarnib has been researched along with abemaciclib in 1 studies

Compound Research Comparison

Studies
(lonafarnib)		Trials
(lonafarnib)		Recent Studies (post-2010)
(lonafarnib)		Studies
(abemaciclib)		Trials
(abemaciclib)		Recent Studies (post-2010) (abemaciclib)
224349035243343

Protein Interaction Comparison

ProteinTaxonomylonafarnib (IC50)abemaciclib (IC50)
Cyclin-T1Homo sapiens (human)0.0734
Cyclin-KHomo sapiens (human)0.065
Cyclin-dependent kinase 1Homo sapiens (human)0.7586
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 26.62
Cyclin-dependent kinase 4Homo sapiens (human)0.0097
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.7484
Cyclin-A2Homo sapiens (human)0.1036
G1/S-specific cyclin-D1Homo sapiens (human)0.0048
G1/S-specific cyclin-E1Homo sapiens (human)0.232
Cyclin-dependent kinase 2Homo sapiens (human)0.1847
G1/S-specific cyclin-D3Homo sapiens (human)0.0112
Cyclin-dependent kinase 7Homo sapiens (human)2.027
Cyclin-dependent kinase 9Homo sapiens (human)0.0693
Cyclin-HHomo sapiens (human)2.6027
CDK-activating kinase assembly factor MAT1Homo sapiens (human)3.106
Cyclin-dependent kinase 6Homo sapiens (human)0.0168
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.405
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.405

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Laufer, S; Pillaiyar, T1

Reviews

1 review(s) available for lonafarnib and abemaciclib

ArticleYear
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication

2022